Morbidity of cholecystectomy and gastric bypass in a national database. BJS 2018; 105: 121-127.
Published: 18th October 2017
Authors: V. Wanjura, E. Szabo, J. Österberg, J. Ottosson, L. Enochsson, G. Sandblom et al.
There is a strong association between obesity and gallstones. However, there is no clear evidence regarding the optimal order of Roux‐en‐Y gastric bypass (RYGB) and cholecystectomy when both procedures are clinically indicated.
Based on cross‐matched data from the Swedish Register for Cholecystectomy and Endoscopic Retrograde Cholangiopancreatography (GallRiks; 79 386 patients) and the Scandinavian Obesity Surgery Registry (SOReg; 36 098 patients) from 2007 to 2013, complication rates, reoperation rates and operation times related to the timing of RYGB and cholecystectomy were explored.
There was a higher aggregate complication risk when cholecystectomy was performed after RYGB rather than before (odds ratio (OR) 1·35, 95 per cent c.i. 1·09 to 1·68;
Cholecystectomy should be performed before, not during or after, RYGB.Full text
You may also be interested in
Authors: A. Storesund, A. S. Haugen, M. Hjortås, M. W. Nortvedt, H. Flaatten, G. E. Eide et al.
Notes: Code correctly
Authors: M. Del Chiaro, K. Søreide
Authors: O. Uleberg, K. Pape, T. Kristiansen, P. R. Romundstad, P. Klepstad
Multicentre study of the prognostic impact of preoperative bodyweight on long‐term prognosis of hepatocellular carcinoma.
Authors: J. J. Yu, F. Shen, T. H. Chen, L. Liang, J. Han, H. Xing et al.
Notes: BMI matters
Authors: G. Polychronidis, F. J. Hüttner, P. Contin, K. Goossen, L. Uhlmann, M. Heidmann et al.
Authors: M. van Putten, S. D. Nelen, V. E. P. P. Lemmens, J. H. M. B. Stoot, H. H. Hartgrink, S. S. Gisbertz et al.
Notes: Practise makes perfect?
Oesophagectomy with or without supraclavicular lymphadenectomy after neoadjuvant treatment for squamous cell carcinoma of the oesophagus.
Authors: S. Mine, M. Watanabe, K. Kumagai, A. Okamura, K. Yamashita, M. Hayami et al.
Notes: Extended dissection not needed
Authors: G. Marchegiani, S. Andrianello, G. Morbin, E. Secchettin, M. D'Onofrio, R. De Robertis et al.
Notes: Duct dilatation no risk alone
Authors: F. F. A. IJpma, T. M. van Gulik
Authors: J. Zheng, S.‐H. Xie, G. Santoni, J. Lagergren
Notes: Diabetes increases risk
Lymph node regression and survival following neoadjuvant chemotherapy in oesophageal adenocarcinoma.
Authors: A. R. Davies, D. Myoteri, J. Zylstra, C. R. Baker, W. Wulaningsih, M. Van Hemelrijck et al.
Notes: Nodal response predicts survival